Home › CMS Finalizes NGS Test National Coverage Determination, Removes Evidence Development for LDTs

CMS Finalizes NGS Test National Coverage Determination, Removes Evidence Development for LDTs

Mar 16, 2018

This article has been updated with information about NGS cancer panels with FDA-approved companion diagnostic indications.

NEW YORK (GenomeWeb) – CMS on Friday finalized the draft national coverage determination it issued last year on next-generation sequencing cancer panels, altering the determination to no longer include coverage with evidence development (CED) for tests that haven't been approved by the US Food and Drug Administration.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02
Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Molecular Diagnostics

  1. Canon Medical Systems Acquires Majority Stake in Cancer Genomic Profiling JV

  2. Premaitha Licenses NIPT Tech From Illumina Under Settlement

  3. India's MolBio Brings Tuberculosis MDx to Point of Care With Help From FIND

    Premium

  4. Biocept Plans to Sell $2.5M in Stock, Warrants

  5. Cepheid Fingerstick HCV Test Receives CE-IVD Clearance

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.